Neurological Disease Efficacy Evaluation
Neurodegenerative diseases, including Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), and Huntington's disease (HD), are irreversible disorders caused by the loss of neuronal structure or function. Our development of FAD4T (AD), SNCA (PD), TDP43 (ALS), SOD1 (ALS) and HTT (HD) mice, created as independent intellectual property, provides a behavioral analysis platform for the conduction of numerous tests, including the Morrise water maze, Y maze, and gait analysis. GemPharmatech additionally offers efficacy evaluation services for several neurodegenerative diseases to expedite the discovery of therapeutic drugs for these conditions.
-
Behavioral Analysis
GemPharmatech provides behavioral analysis services, including motor function, learning, cognitive disorders, affective disorder, etc.
-
In Vivo Drug Efficacy Evaluation
GemPharmatech conduct functional testing of the nervous system and behavioral analyses utilizing mouse models of neurological diseases.
-
Delivering Therapeutics Across the Blood-Brain Barrier (BBB)
To facilitate drug delivery across the blood-brain barrier, GemPharmatech is actively developing a series of humanized mouse models targeting the transferrin receptor, which will provide innovative tools for drug discovery and therapeutic strategy optimization.
-
Parkinson’s Disease Rat Model
Parkinson disease (PD) is a progressive neurodegenerative disease that is characterized by a combination of motor and non-motor symptoms. GemPharmatech has successfully developed a PD rat model, providing a powerful tool for in-depth research and drug development, enabling a more comprehensive understanding and potential therapeutic interventions for PD.